ReShape taps Allergan vet Bandy for CEO | Personnel Moves, April 3 2019

ReShape LifesciencesReShape Lifesciences (NSDQ:RSLS) said last week that it named Allergan (NYSE: AGN) veteran Barton Bandy to replace Dan Gladney in the corner office, effective April 1.

Gladney, who announced his retirement in January, is staying on as chairman. Bandy spent a decade at Inamed until its $3.2 billion purchase by Allergan in 2005.

“I am very pleased to welcome Bart to the ReShape team. His experience and success – particularly with the Lap-Band business at Inamed and Allergan – in addition to his leadership track record since then make Bart the perfect next leader for ReShape,” Gladney said in prepared remarks. “I would like to thank the ReShape team for the hard work and dedication during my time as CEO and I look forward to assisting in a smooth transition and continuing on as a dedicated chairman of the board.”

“This is a very exciting time to be joining ReShape. My experience leading and building medical device organizations and the company’s strategic shift to the proven Lap-Band product, which I know very well, present immediate growth opportunities,” Bandy added. “It is also an incredibly exciting time to see the next-generation, revolutionary ReShape Vest through clinical studies to commercialization. I am thrilled to be part of ReShape Lifesciences and to help drive its future success.”

 Alcon lures HP CFO Stonesifer as finance chief
Novartis (NYSE:NVS) eye business Alcon said it lured Hewlett Packard HPE CFO Timothy Stonesifer to be its new CFO ahead of Alcon’s April 9 spinout.

Current CFO David Murray “decided for family reasons to return to Europe and remain with Novartis,” the company said.

“Tim joins us at an exciting time as we become an independent organization and the world’s leading eye care device company,” Alcon CEO David Endicott said. “He is an outstanding addition to our leadership team, bringing extraordinary financial acumen and deep experience in capital markets transactions, having served as CFO for numerous companies. Tim is also respected in the financial community and known for his ability to develop top-performing finance organizations that deliver results.”

“I am excited to join the exceptional team at Alcon,” Stonesifer added. “For more than 70 years, Alcon has been synonymous with eye care. We share a passion for serving customers and a vision for delivering innovative products that will continue to shape the industry while driving profitable growth.”
Read more

 Exsomed names Maya as CEO
ExsoMed said it named former Tenex Health CEO Bill Maya as its new chief executive effective March 16. Interim CEO Jon Holder moved to the chief revenue officer slot, the company said.
Read more

 iCad promotes Stevens to president
iCad (NSDQ:ICAD) said it promoted its strategy & commercial chief, Stacey Stevens, to president.
Read more

 Ex-J&J litigation head is Stryker’s new chief legal officer
Stryker (NYSE:SYK) tapped the worldwide litigation head at Johnson & Johnson (NYSE:JNJ), Rob Fletcher, to be its new chief legal officer following the April 22 departure of Michael Hutchinson, who is slated to move to VP & advisor to CEO Kevin Lobo.
Read more

PolarityTE reveals SEC investigation

PolarityTE

PolarityTE (NSDQ:PTE) this week revealed that it is the target of an SEC investigation into possible violations of federal securities laws.

The Salt Lake City, Utah-based company said that it received a copy of a formal order of investigation from the SEC on March 4, exploring possible violations of fraud and price manipulations, according to an SEC filing.

Read the whole story on our sister site, Drug Delivery Business News

The post PolarityTE reveals SEC investigation appeared first on MassDevice.

PolarityTE registers bone repair product with FDA

PolarityTE updated logoPolarityTE (NSDQ:PTE) said last week that it registered its bone repair product, OsteoTE, with the FDA.

The Utah-based company’s technology is an autologous, homologous product designed to repair, reconstruct and replace bone using a patient’s own cells.

Get the full story at our sister site, Drug Delivery Business News.

The post PolarityTE registers bone repair product with FDA appeared first on MassDevice.

PolarityTE responds to short-seller report

PolarityTe

PolarityTE yesterday responded to a scathing report from Citron Research which accused the company of fraud, saying that the report was used by short sellers to drop the company’s share value.

The Salt Lake City, Utah.-based company said that the publication is “well-known to be used as a tool by notorious short sellers” and that they are “designed to negatively impact PolarityTE’s share price for the benefit of short sellers and other colluding agents.” The company goes on to say that the report contains false and misleading assertions contrary to the company and its physician partners’ views.

PolarityTE saw major trading yesterday after the report was released, with its shares dropping approximately 17%.

The company said that it noted in a press release earlier this month that it had reported “unusual and suspected illegal trading activity” in its securities to the appropriate regulatory authorities.

“This conduct from Citron—whose founder has been barred from trading on certain exchanges in the past due to manipulative activity—is consistent with a pattern and practice of deliberate distortion to negatively impact PolarityTE. Those engaging in illegal manipulative trading activity such as “short and distort” schemes, “naked short” selling, and pre-arranged trading are accountable under federal laws enforced by the regulators. The company will not be distracted from its patient-focused mission,” PolarityTE said in its release.

Shares in PolarityTE have risen 4.7% so far today, at $12.68 as of 3:26 p.m. EDT.

The post PolarityTE responds to short-seller report appeared first on MassDevice.

BD lifts Bard vet DeFord to CTO | Personnel Moves – June 4, 2018

Becton Dickinson (NYSE:BDX) said last Friday it is lifting former C.R. Bard science, technology and clinical affairs senior VP John DeFord to the role of chief technology officer and exec VP.

Since acquiring Bard in a $24 billion deal that closed last December, DeFord has served as BD interventional segment R&D SVP, the Franklin Lakes, N.J.-based company said.

DeFord originally joined Bard as science & tech VP in 2004, and had previously served life sciences managing director for venture capital fund Early Stage Partners and as prez & CEO of Cook Inc, which is now known as Cook Medical. He also currently serves on NuVasive‘s (NSDQ:NUVA) board of directors, BD said.

“John is a recognized leader with more than 25 years of experience in the medical device industry, with expertise overseeing innovative R&D and technology-based initiatives that have made significant effects on saving and improving lives for patients around the world. He will drive organizational culture, capabilities, products and technology-enabled services to further strengthen the BD innovation funnel, while advancing the world of health through new innovations and solutions for our customers and patients,” prez Tom Polen said in a press release.

 Teleflex global ops SVP Kennedy to retire next year

Teleflex (NYSE:TFX) said last week that its global ops senior VP Thomas Kennedy will retire from the company at the end of next March.

Kennedy will remain in his present position until a replacement is appointed, the Wayne, Penn.-based company said. After a replacement has been named, Kennedy will stay on to aid in the transition.

Read more

 Merit Medical CFO Birkett resigns

Merit Medical (NSDQ:MMSI) said late last month that its chief financial officer and treasurer Bernard Birkett has resigned from the company.

The South Jordan, Utah-based company said that it appointed current accounting VP & corporate controller Raul Parra Jr. as its interim CFO. Parra previously held the position of financial reporting director from December 2009 to July 2012.

Before joining Merit, Parra held the position of auditor with Deloitte & Touche from 2003 to 2009.

Read more

 Integer CFO Haire steps away

Integer Holdings (NYSE:ITGR) said late last month that its exec VP and CFO Gary Haire has separated from the company, effective May 23.

The Frisco, Texas-based company said it has begun a search for a successor, and that until one is found, Jeremy Friedman will serve as interim CFO.

Friedman is currently responsible for the company’s supply chain, environmental, health, safety and security needs, as well as the divestiture of the company’s advanced spinal & orthopedics product line.

Read more

 EctoSense taps McCourt as CEO

Sleep-disorder focused digital health and medical device company EctoSense said last Friday it named Ciaran McCourt as CEO.

Prior to joining Belgium-based EctoSense, McCourt served as CEO of eDiets and Unilever biometric sensor spin out MiLife. He also served as international biz dev director for BiancaMed, which was acquired by ResMed (NYSE:RMD) in 2014.

“We are very pleased to get someone with Ciaran’s depth of experience on board to drive the company’s high ambitions in delivering scalable and clinically validated diagnostics and services in sleep disorder care globally,” co-founder Bart Van Pee said in a press release

“I am very pleased to take up this role with Ectosense operating at the leading edge of developing innovative respiratory diagnostics, beginning in the domain of sleep apnea with the Nightowl device. The device is a perfectly timed step change in sleep apnea screening and diagnosis given its ease of use and cost of delivery just as patients and providers are seeking ever more convenient devices without sacrificing diagnostic efficacy. I believe the engineering, clinical, and design strengths of Ectosense will ensure its place in the new generation of device companies that will improve access to important disease diagnostics and services,” CEO McCourt said in a prepared statement.

Read more

The post BD lifts Bard vet DeFord to CTO | Personnel Moves – June 4, 2018 appeared first on MassDevice.